Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goudreau

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Alzheimer'S Disease : JAD|September 11, 2008
Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's diseaseKelly L Janis, Ryan T Brennan, Robert E Drolet, et al.
Neurotoxicology|February 21, 2012
Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expressionMatthew Benskey, Bahareh Behrouz, Johan Sunryd, et al.
BMC Veterinary Research|September 26, 2020
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunctionJessica S Fortin, Matthew J Benskey, Keith J Lookingland, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 21, 2015
Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenaseChelsea T Tiernan, Ethan A Edwin, Hae-Young Hawong, et al.
Journal of the Neurological Sciences|June 12, 2016
Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North AmericaJohn L Goudreau, Adriana Pérez, Michael J Aminoff, et al.
Parkinsonism & Related Disorders|May 16, 2018
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's diseaseD Luke Fischer, Peggy Auinger, John L Goudreau, et al.
Frontiers in Neurology|December 5, 2022
<i>BDNF</i> rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's diseaseD Luke Fischer, Peggy Auinger, John L Goudreau, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's diseaseJohn L Goudreau, Demetrius M Maraganore, Matthew J Farrer, et al.
The Biochemical Journal|November 12, 2009
Activation of autophagy through modulation of 5'-AMP-activated protein kinase protects pancreatic beta-cells from high glucoseDiana Han, Byungho Yang, L Karl Olson, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|May 29, 2012
Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout miceTyrell J Simkins, Kelly L Janis, Alison K McClure, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Alzheimer'S Disease : JAD|September 11, 2008
Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's diseaseKelly L Janis, Ryan T Brennan, Robert E Drolet, et al.
Neurotoxicology|February 21, 2012
Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expressionMatthew Benskey, Bahareh Behrouz, Johan Sunryd, et al.
BMC Veterinary Research|September 26, 2020
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunctionJessica S Fortin, Matthew J Benskey, Keith J Lookingland, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 21, 2015
Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenaseChelsea T Tiernan, Ethan A Edwin, Hae-Young Hawong, et al.
Journal of the Neurological Sciences|June 12, 2016
Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North AmericaJohn L Goudreau, Adriana Pérez, Michael J Aminoff, et al.
Parkinsonism & Related Disorders|May 16, 2018
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's diseaseD Luke Fischer, Peggy Auinger, John L Goudreau, et al.
Frontiers in Neurology|December 5, 2022
<i>BDNF</i> rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's diseaseD Luke Fischer, Peggy Auinger, John L Goudreau, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's diseaseJohn L Goudreau, Demetrius M Maraganore, Matthew J Farrer, et al.
The Biochemical Journal|November 12, 2009
Activation of autophagy through modulation of 5'-AMP-activated protein kinase protects pancreatic beta-cells from high glucoseDiana Han, Byungho Yang, L Karl Olson, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|May 29, 2012
Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout miceTyrell J Simkins, Kelly L Janis, Alison K McClure, et al.
Pageof 5